Short Interest in CytoDyn Inc. (OTCMKTS:CYDY) Rises By 7.4%

CytoDyn Inc. (OTCMKTS:CYDY) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 8,617,700 shares, an increase of 7.4% from the July 15th total of 8,024,100 shares. Based on an average daily trading volume, of 2,801,300 shares, the short-interest ratio is currently 3.1 days.

CytoDyn Stock Performance

Shares of CYDY stock traded up $0.01 during midday trading on Friday, reaching $0.12. 1,020,073 shares of the company were exchanged, compared to its average volume of 2,611,157. The company’s 50 day moving average price is $0.14 and its two-hundred day moving average price is $0.16. The company has a market cap of $131.73 million, a P/E ratio of -2.49 and a beta of 0.15. CytoDyn has a 12 month low of $0.11 and a 12 month high of $0.42.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.